Allergy Therapeutics plc has been mentioned in a Form 8.5 (EPT/RI) disclosure by Panmure Gordon (UK) Limited. The disclosure states that Panmure Gordon (UK) Limited, as an exempt principal trader, has made purchases and sales of Allergy Therapeutics' 0.1p ordinary shares. The purchases amounted to 4,930,363 securities, with the highest price per unit paid at 0.013 and the lowest price per unit paid at 0.01257. On the other hand, the sales totaled 4,615,383 securities, with the highest and lowest prices per unit received both at 0.013.
The disclosure does not mention any cash-settled derivative transactions or stock-settled derivative transactions, including options, related to Allergy Therapeutics' securities. It also states that there are no indemnity or option arrangements, agreements, or understandings between Panmure Gordon (UK) Limited and any party to the offer or any person acting in concert with a party to the offer. Additionally, there are no agreements, arrangements, or understandings relating to options or derivatives.
The disclosure was made on October 20, 2023, and the contact person for further information is Freddie Wooding, with a telephone number of +44 (0)20 7886 2969. The disclosure emphasizes that public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service, and the Panel's Market Surveillance Unit is available for consultation regarding the Code's dealing disclosure requirements.